Management

Zoltan Kiss, Ph.D. - He founded ZK Obesity Control biotechnological company in 2021 for which now he serves as the President and CEO. This family-owned company is based on his research showing that some of the newly synthesized organic compounds can help to maintain body weight of genetically obese mice.

*About the Founder: Zoltan Kiss, Ph.D., had an extensive academic research career before founding and leading several biotechnological companies. Until 2004, he was Professor and Section Leader at the University of Minnesota. Prior to that, he was a Senior Investigator at the National Cancer Institute (4 years) and held several faculty positions in the U.S. and Europe. Dr. Kiss holds a Ph.D. degree, and his research so far has resulted in 114 peer-reviewed articles and 27 issued international patents as well as 5 filed patent applications on the treatments of cancer cachexia, wounds, and various metabolic disorders, such as diabetes, including specific treatment of excess visceral fat. All his issued patents are now owned by MNPHARM, LLP, a Minnesota biotech company. Most recently, Dr. Kiss has been focusing on (1) using organic compounds to stabilize body weight for periods when treatments with weight loss drugs are stopped, (2) finding effective interventions to normalize excess visceral obesity and determining the nature of relationships between visceral fat and various metabolic disorders, and (3) methods to prevent cancer cachexia.